natgillin/translations-raw huggingface dataset:
Therefore, Optimark must not be used in patients who have had or are undergoing liver transplantation and in neonates (see section 4.3).
Zato se zdravilo Optimark pri bolnikih, pri katerih so opravili ali opravljajo presaditev jeter, in pri novorojenčkih ne sme uporabljati (glejte poglavje 4.3).
Frequency unknown: Benign/malignant kidney tumours (microcysts, oncocytoma, or collecting duct renal carcinoma) (in long-term therapy).
Neznana pogostnost:benigni/maligni ledvični tumorji (mikrociste, onkocitomi in karcinomi Bellinijevih vodov (pri dolgotrajnem zdravljenju).
Section 4 Possible side effects:
Poglavje 4 Možni neželeni učinki:
In particular, valproateinduced acute liver failure and liver-related deaths have been reported at a higher rate in patients with hereditary neurometabolic syndromes caused by mutations in the gene for the mitochondrial enzyme polymerase γ (POLG), e.g. Alpers-Huttenlocher Syndrome.
O akutni odpovedi jeter in smrti, povezani z jetri, ki ju je povzročil valproat, so pogosteje poročali pri bolnikih z dednimi nevrometabolnimi motnjami, ki jih povzročajo mutacije gena za mitohondrijski encim polimerazo γ (POLG), npr. sindromom AlpersHuttenlocher.
Therefore <invented name> must not be used in patients with severe renal impairment, in patients in the perioperative liver transplantation period and in neonates (see section 4.3).
Kontrastno sredstvo <izmišljeno ime> se ne sme uporabljati pri bolnikih s hudo okvaro ledvic, pri bolnikih v perioperativnem obdobju presaditve jeter in pri novorojenčkih (glejte poglavje 4.3).
• in patients with severe renal impairment (GFR < 30 ml/min/1.73m2) and/or acute kidney injury.
• pri bolnikih s hudo ledvično okvaro (GFR < 30 ml/min/1,73 m²) in/ali akutno poškodbo ledvic,
Frequency unknown: Microcysts, oncocytoma and collecting duct renal carcinoma (in long-term therapy) (see Section 4.4).
Neznana pogostnost: mikrociste, onkocitomi in karcinomi Bellinijevih vodov (pri dolgotrajnem zdravljenju) (glejte poglavje 4.4).
There have been very rare reports of an immune-mediated necrotizing myopathy (IMNM) during or after treatment with some statins.
Med zdravljenjem z nekaterimi statini oziroma po njem so zelo redko poročali o imunsko posredovani nekrotizirajoči miopatiji (IMNM).
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of <invented name> and some other gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR < 30 ml/min/1.73m2) and/or acute kidney injury.
Poročali so o nefrogeni sistemski fibrozi (NSF), povezani z uporabo kontrastnega sredstva <izmišljeno ime> in nekaterih drugih kontrastnih sredstev, ki vsebujejo gadolinij, pri bolnikih z akutno ali kronično hudo okvaro ledvic (GFR < 30 ml/min/1,73 m2) in/ali akutno poškodbo ledvic.
Patients with iImpaired renal function
Bolniki z Okvarjeno delovanje okvarjenim delovanjem ledvic
Package Leaflet
Okvara ledvic
Having considered the available evidence the PRAC has agreed that the MAH of Omniscan, Optimark and Magnevist should submit a variation within 2 months, to amend the product information as described below (new text underlined / text to be removed strikethrough).
Po preučitvi razpoložljivih dokazov se je odbor PRAC strinjal, da morajo imetniki dovoljenja za promet z zdravili Omniscan, Optimark in Magnevist v dveh mesecih predložiti vlogo za spremembo informacij o zdravilu, kot je opisano spodaj (novo besedilo podčrtano/besedilo za izbris prečrtano).
Taken into account all available data PRAC agreed that all MAHs for paroxetine containing products should submit a variation within 2 months to amend the product information (section 4.8 of the SmPC and package leaflet) as described below (new text underlined).
Ob upoštevanju vseh razpoložljivih podatkov se je odbor PRAC strinjal, da morajo vsi imetniki dovoljenja za promet z zdravili, ki vsebujejo paroksetin, v 2 mesecih predložiti vlogo za spremembo informacij o zdravilu (poglavja 4.8 v povzetku glavnih značilnosti zdravila in navodila za uporabo), kot je opisano spodaj (novo besedilo je podčrtano).
Talk to your doctor <or> , <pharmacist> <or nurse> before <taking> <using> <product name>: You know that there is a genetic problem causing a mitochondrial disorder in your family.
Pred začetkom <jemanja> <uporabe> <ime zdravila> se posvetujte <z> zdravnikom <ali> <farmacevtom> <ali> <medicinsko sestro>.
The marketing authorisation holders for valproate (and related substances) containing medicinal products should submit a variation within 2 months to amend the product information as described below (new text underlined).
Imetniki dovoljenja za promet z zdravili, ki vsebujejo valproat (in sorodne učinkovine), morajo v 2 mesecih predložiti vlogo za spremembo informacij o zdravilu, kot je opisano spodaj (novo besedilo je podčrtano).
Renal tumours: Cases of microcysts, oncocytomas and collecting duct renal carcinoma have been reported in patients with severe renal impairment who received lithium for more than 10 years (see Section 4.8).
Ledvični tumorji: Pri bolnikih s hudo okvaro ledvic, ki so prejemali litij več kot 10 let, so poročali o mikrocistah, onkocitomih in karcinomih Bellinijevih vodov (glejte poglavje 4.8).
Therefore, the Marketing Authorisation Holders of lithium containing medicinal products should submit a variation within 2 months, to amend the product information as described below (new text underlined).
Imetniki dovoljenja za promet z zdravili, ki vsebujejo litij (in sorodne učinkovine), morajo zato v dveh mesecih predložiti vlogo za spremembo informacij o zdravilu, kot je opisano spodaj (novo besedilo podčrtano).
4.3 Contraindications <invented name> is contraindicated in patients with severe renal impairment (GFR <30ml/min/1.73m2) and/or acute kidney injury, in patients in the perioperative liver transplantation period and in neonates up to 4 weeks of age (see section 4.4).
Kontrastno sredstvo <izmišljeno ime> je kontraindicirano pri bolnikih s hudo okvaro ledvic (glomerularna filtracija GFR < 30 ml/min/1,73 m2) in/ali akutno poškodbo ledvic, pri bolnikih v perioperativnem obdobju presaditve jeter in pri novorojenčkih do 4. tedna starosti (glejte poglavje 4.4).
Renal impairment <invented name> is contraindicated in patients with severe renal impairment (GFR < 30 ml/min/1.73m2) and/or acute kidney injury and in patients in the perioperative liver transplantation period (see section 4.3).
Kontrastno sredstvo <izmišljeno ime> je kontraindicirano pri bolnikih s hudo okvaro ledvic (glomerulna filtracija (GFR) < 30 ml/min/1,73 m2) in/ali akutno poškodbo ledvic in pri bolnikih v perioperativnem obdobju presaditve jeter (glejte poglavje 4.3).
Optimark is contraindicated in patients with severe renal impairment (GFR < 30 ml/min/1.73m2) and/or acute renal injury and in patients who have had liver transplantation or in patients in the perioperative liver transplantation period (see section 4.3).
Zdravilo Optimark je kontraindicirano pri bolnikih s hudo ledvično okvaro (stopnja glumeralne filtracije (GFR) < 30 ml/min/1,73 m²) in/ali akutno poškodbo ledvic in pri bolnikih, pri katerih so opravili presaditev jeter ali so v perioperativnem obdobju presaditve jeter (glejte poglavje 4.3).
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of Optimark and some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR <30ml/min/1.73m²) and/or acute kidney injury.
Pri bolnikih s hudo akutno ali kronično ledvično okvaro (GFR < 30 ml/min/1,73 m2 ) in/ali akutno poškodbo ledvic so poročali o nefrogeni sistemski fibrozi (NSF), povezani z uporabo zdravila Optimark in nekaterih kontrastnih sredstev, ki vsebujejo gadolinij.
• The medicine should be taken at the same time each day, usually in the morning.
• Zdravilo je treba vzeti vsak dan ob istem času, običajno je to zjutraj.
Member State EU / EEA
Država članica EU/EGP
This especially applies to the following medicines:
To še posebno velja za naslednja zdravila:
The fourth issue was regarding the time of maximal effects.
Četrto vprašanje se je nanašalo na čas največjih učinkov.
Invented name Name
Izmišljeno ime
• Swallow the tablet with a glass of water.
• Tableto zaužijte s kozarcem vode.
Also, the safety profile of the components could be considered well known.
Prav tako se lahko upošteva, da je varnostni profil sestavin dobro znan.
No interaction
Brez interakcij
• if you are unable to urinate.
• če ne morete urinirati.
There were significant divergences in the contraindications.
V kontraindikacijah so bila pomembna razhajanja.
2 & 4, rue Lionel Terray 92500 RUEIL-MALMAISON, France
2 & 4, rue Lionel Terray 92500 RUEIL-MALMAISON, Francija
The inclusion of syncope in section 4.8 is also justified.
Prav tako je utemeljena vključitev sinkope v poglavje 4.8.
You should see your doctor immediately if you experience symptoms of angioedema, such as:
Takoj morate k zdravniku, če pride do simptomov angioedema, kot so:
But according to the European hypertension treatment Guidelines (Mancia et al., Eur Heart J 2007;28(12):1462-536) it is no longer warranted.
Vendar pa glede na Evropske smernice zdravljenja hipertenzije (Mancia et al., Eur Heart J 2007;28(12):1462-536) to ni več utemeljeno.
Also, a paragraph regarding interaction with tetracycline has been deleted.
Poleg tega je bil izbrisan odstavek o medsebojnem delovanju s tetraciklinom.
The terminal half-life is 6-15 h.
Končni razpolovni čas je 6-15 ur.
In most patients, maximal effects are observed within 4 weeks.
Pri večini bolnikov so največji učinki opazni v štirih tednih.
This makes it all the more important for you to keep your appointments with your doctor even if you are feeling well.
Zato je zelo pomembno, da hodite na preglede k svojemu zdravniku, tudi če se počutite dobro.
However, in some patients, 4-8 weeks treatment may be required.
Vendar pa nekateri bolniki utegnejo potrebovati 4-8-tedensko zdravljenje.
If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.
Če med zdravljenjem pride do fotosenzitivnostne reakcije, je priporočena prekinitev zdravljenja.
• it may cause increased sensitivity of the skin to sun.
• ker lahko povzroči povečano občutljivost kože na sončno svetlobo.
Your doctor may need to check the amount of potassium in your blood regularly.
Zdravnik vam bo moral verjetno redno pregledovati količino kalija v krvi.
Your doctor will tell you exactly how many tablets of Diovan Comp to take.
Zdravnik vam bo povedal točno koliko tablet zdravila Diovan Comp morate jemati.
Norway Novartis Norge AS Postboks 237 Økern 0510 Oslo
Norveška Novartis Norge AS Postboks 237 Økern 0510 Oslo
Other metabolic disturbances
Druge metabolične motnje
The magnitude of these effects is small and has minimal clinical importance.
Vendar so te razlike majhne in imajo le majhen klinični pomen.
Hungary Novartis Hungaria Kft. Bartók Béla út 43-47
Madžarska Novartis Hungaria Kft. Bartók Béla út 43-47
If any of the above apply to you, do not take this medicine and speak to your doctor.
Če karkoli od zgoraj navedenega velja za vas, ne jemljite tega zdravila in se pogovorite s svojim zdravnikom.
In conclusion, the CHMP agreed the following: "The antihypertensive effect is substantially present within 2 weeks.
Za zaključek je CHMP sprejel sledeče: „Antihipertenzivni učinek je močno prisoten v dveh tednih.
Avoid taking alcohol until you have talked to your doctor.
Izogibajte se uživanju alkohola, dokler se ne posvetujete s svojim zdravnikom.
Dose titration with the individual components is recommended.
Priporoča se titracija odmerka s posameznimi sestavinami.
Calcium salts and vitamin D
Kalcijeve soli in vitamin D
The use of Diovan Comp in children and adolescents (below the age of 18 years) is not recommended.
Uporaba zdravila Diovan Comp pri otrocih in mladostnikih (starih manj kot 18 let) ni priporočena.
These contraindications were deleted in the revised PI as the CHMP found enough justifications and agreed about the four exclusion.
Te kontraindikacije so bile izbrisane v popravljenih informacijah o zdravilu, saj je CHMP ugotovil dovolj utemeljitev in se je strinjal glede teh štirih izključitev.
The increase in mean AUC is linear and dose proportional in the therapeutic range.
Večanje povprečne AUC je linearno in sorazmerno odmerkom v terapevtskem območju.
The following contra-indications were not included in all Member States: - Hepatic encephalopathy - Biliary obstruction - Gout -Addison's disease
Sledeče kontraindikacije niso bile vključene v vseh državah članicah: - jetrna encefalopatija - biliarna obstrukcija - protin - Addisonova bolezen
Valsartan shows multiexponential decay kinetics (t½α <1 h and t½ß about 9 h).
Valsartan kaže multieksponentno kinetiko upadanja (t½α <1 ura in t½ß približno 9 ur).
Both of these substances help to control high blood pressure (hypertension).
Obe učinkovini pomagata uravnavati visok krvni tlak (hipertenzijo).
The second issue raised in the LoOI was about the step titration.
Drugo vprašanje, postavljeno na spisek odprtih vprašanj, je bilo glede postopne titracije.
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders has been assessed based on the documentation submitted and the scientific discussion within the Committee,
- Povzetki glavnih značilnosti zdravila, označevanje in navodila za uporabo, ki jih je predlagal imetnik dovoljenja za promet z zdravilom, so bilo ovrednoteni na podlagi predložene dokumentacije in znanstvenih razprav znotraj Odbora.
• Do not change the dose or stop taking the tablets without consulting your doctor.
• Ne spreminjajte odmerka in ne prenehajte jemati tablet, ne da bi se prej pogovorili z zdravnikom.
“Treatment of essential hypertension in adults”
„Zdravljenje esencialne hipertenzije pri odraslih“
• The usual dose of Diovan Comp is one tablet per day.
• Običajni odmerek zdravila Diovan Comp je ena tableta na dan.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF DIOVAN COMP AND ASSOCIATED NAMES (SEE ANNEX I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA DIOVAN COMP IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
Section 4.2 - Posology and Method of Administration Under this section the CHMP identified several area of disagreement.
Poglavje 4.2 - Odmerjanje in način uporabe CHMP je v tem poglavju ugotovil več področij neskladja.
Lowering your blood pressure to normal reduces the risk of developing these disorders.
Z znižanjem krvnega tlaka se običajno zmanjša tveganje za razvoj teh bolezni.
No information is available regarding the use of valsartan during breastfeeding.
Ni podatkov o uporabi valsartana med dojenjem.
A specific warning for athletes was to be deleted as the CHMP considered that drugs should not be taken for sport purposes.
CHMP je dal izbrisati posebno opozorilo za športnike, saj je mnenja, da se zdravila ne smejo uporabljati v športne namene.
Clinical data, however, demonstrate that the antihypertensive effect of all doses of valsartan/HCTZ is substantially present within 2 weeks, and maximal effects are attained within 4 weeks.
Vendar pa klinični podatki dokazujejo, da je antihipertenzivni učinek vseh odmerkov valsartana/hidroklorotiazida močno prisoten v dveh tednih in da so največji učinki doseženi v štirih tednih.
• if the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.
• če sta vaši ravni kalija ali natrija v krvi nižji od normalnih ali če je vaša raven kalcija v krvi višja od normalne kljub zdravljenju.
In conclusion, the CHMP recommended, in line with the recently finalized referral procedure for Cozaar Comp, that “angiotensin-II-antagonist” is changed to “valsartan” in this indication.
Za zaključek je CHMP priporočil, da se, v skladu z nedavno zaključenim napotitvenim postopkom za zdravilo Cozaar Comp, za to indikacijo „antagonist angiotenzina II spremeni v „valsartan
Before you drive a vehicle, use tools or operate machines or carry out other activities that require concentration, make sure you know how Diovan Comp affects you.
Vpliv na sposobnost upravljanja vozil in strojev Preden začnete voziti, uporabljati orodje, upravljati stroje ali izvajati druge dejavnosti, ki zahtevajo zbranost, morate zagotovo vedeti, kako zdravilo Diovan Comp deluje na vas.
• severe upper stomach pain; lack or low levels of different blood cells
• huda bolečina v zgornjem delu trebuha; pomanjkanje ali znižano število različnih krvnih celic
Hydrochlorothiazide also accumulates in erythrocytes at approximately 1.8 times the level in plasma.
Hidroklorotiazid se poleg tega kopiči v eritrocitih v približno 1,8-krat večji koncentraciji kot v plazmi.
Although hydrochlorthiazide is excreted into human milk, this does not warrant a contraindication.
Čeprav se hidroklorotiazid izloča v materinem mleku, to ne utemeljuje kontraindikacije.
If this applies to you, the use of Diovan Comp is not recommended.
Če pride do tega pri vas, uporaba zdravila Diovan Comp ni priporočena.
If you take more Diovan Comp than you should If you experience severe dizziness and/or fainting, lay down and contact your doctor immediately.
Če ste vzeli večji odmerek zdravila Diovan Comp, kot bi smeli Če občutite hudo omotičnost in/ali omedlevico, lezite in se takoj povežite s svojim zdravnikom.
Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug.
Valsartan se izloča predvsem z blatom (približno 83 % odmerka) in z urinom (približno 13 % odmerka), večinoma v obliki nespremenjenega zdravila.
No studies on the effect of Diovan Comp on the ability to drive and use machines have been performed.
Študij o vplivu zdravila Diovan Comp na sposobnost vožnje in upravljanja s stroji niso izvedli.
There is currently no experience on the safe use of Diovan Comp in patients who have recently undergone kidney transplantation.
Trenutno ni izkušenj o varni uporabi zdravila Diovan Comp pri bolnikih, ki so jim nedavno presadili ledvico.
These side effects may occur with certain frequencies, which are defined as follows: very common: affects more than 1 user in 10 common: affects 1 to 10 users in 100 uncommon: affects 1 to 10 users in 1,000 rare: affects 1 to 10 users in 10,000 very rare: affects less than 1 user in 10,000 not known: frequency cannot be estimated from the available data
Neželeni učinki se pojavljajo s pogostnostjo, ki je opredeljena spodaj: zelo pogosti: prizadenejo več kot 1 od 10 uporabnikov pogosti: prizadenejo 1 do 10 od 100 uporabnikov občasni: prizadenejo 1 do 10 od 1.000 uporabnikov redki: prizadenejo 1 do 10 od 10.000 uporabnikov zelo redki: prizadenejo manj kot 1 od 10.000 uporabnikov neznana: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov
Such patients should therefore be advised about the possibility of hyponatraemic reactions, and should be monitored accordingly.
Take bolnike je treba opozoriti na možnost razvoja hiponatriemije in jih temu ustrezno spremljati.
Treatment of essential hypertension in adults.
Zdravljenje esencialne hipertenzije pri odraslih.
Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.
Zaradi uživanja alkohola se vam lahko krvni tlak še bolj zniža in/ali se poveča možnost, da postanete vrtoglavi ali omotični.
• Do not use Diovan Comp after the expiry date which is stated on the pack.
• Zdravila Diovan Comp ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor.
Valsartan nima delnega agonističnega učinka na receptorje AT1 in ima veliko (približno 20.000-kratno) večjo afiniteto za receptorje AT1 kot za receptorje AT2.
The toxicological target organ was the kidney, the reaction being more marked in the marmoset than the rat.
Toksikološki ciljni organ so bile ledvice, pri čemer je bila reakcija bolj izrazita pri marmozetkah kot pri podganah.
− Second and third trimester of pregnancy (section 4.4 and 4.6).
- Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
• itching or red skin
• srbenje ali rdečina kože
Like many other medicines used to treat high blood pressure, Diovan Comp may occasionally cause dizziness and affect the ability to concentrate.
Kot številna druga zdravila za zdravljenje visokega krvnega tlaka lahko zdravilo Diovan Comp v redkih primerih povzroči omotičnost in vpliva na sposobnost koncentracije.
• if you have recently received a new kidney.
• če so vam pred kratkim presadili ledvico.
• if you are taking high doses of water tablets (diuretics).
• če jemljete visoke odmerke zdravil za odvajanje vode (diuretikov).
Section 4.8 - Undesirable Effects
Poglavje 4.8 - Neželeni učinki
The efficacy of valsartan/HCTZ was maintained long-term (1-3 yrs) with no significant adverse events being observed compared to short-term therapy.
Učinkovitost valsartana/hidroklorotiazida so vzdrževali dolgoročno (1-3 leta) in ob tem, v primerjavi s kratkotrajnim zdravljenjem, niso opazili nikakršnih pomembnih neželenih učinkov.
A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.
Pri nekaterih starejših bolnikih so opazili nekoliko večjo sistemsko izpostavljenost valsartanu v primerjavi z mladimi osebami; vendar se ni pokazalo, da bi imelo to kakšen kliničen pomen.
Patients with primary hyperaldosteronism should not be treated with Diovan Comp as their reninangiotensin system is not activated.
Bolnikov s primarnim hiperaldosteronizmom se ne sme zdraviti z zdravilom Diovan Comp, saj njihov renin-angiotenzinski sistem ni aktiviran.
• swelling and blistering of the skin (due to increased sensitivity to sun)
• otekanje kože in pojavljanje mehurjev (zaradi povečane občutljivosti na sončno svetlobo)
• lithium, a medicine used to treat some types of psychiatric illness
• litij, zdravilo za zdravljenje nekaterih vrst psihiatričnih bolezni,
The CHMP, in the interest of readability, revised this section and agreed on including information about the thiazide.
CHMP je v interesu berljivosti pregledal to poglavje in se strinjal glede vključitve podatkov o tiazidu.
• Valsartan belongs to a class of medicines known as “angiotensin II receptor antagonists”, which help to control high blood pressure.
• Valsartan sodi v skupino zdravil, znano pod imenom "antagonisti receptorjev angiotenzina II", ki pomagajo uravnavati visok krvni tlak.
This should be taken into account during dose titration.
Pri titraciji odmerka je treba to upoštevati.
Stopping your treatment with Diovan Comp may cause your high blood pressure to get worse.
Prenehanje zdravljenja z zdravilom Diovan Comp lahko povzroči poslabšanje vašega visokega krvnega tlaka.
Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po pogostnosti, najbolj pogosti najprej, in sicer po naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov).
• if you have had allergic reactions with the use of other blood pressure-lowering agents of this class (angiotensin II receptor antagonists) or if you have allergy or asthma.
• če ste imeli alergijsko reakcijo, ko ste uporabljali druga zdravila za zniževanje krvnega tlaka iz te skupine (zaviralcev angiotenzinskih receptorjev II) ali če imate alergijo ali astmo.
Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.
Rezultati epidemioloških študij kažejo, da dolgotrajno zdravljenje s hidroklorotiazidom zmanjšuje tveganje za kardiovaskularne bolezni in smrt.